Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | MMP14 | P50281 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8751807 | 0.88 | NQO1 (0.63) | NQO1KDM4EALDH1A1TDP1TSHR | |
| SCHEMBL3631389 | 0.84 | KDM4E (0.50) | NQO1KDM4EALDH1A1MAOBDRD2 | |
| SCHEMBL18358 | 0.83 | NQO1 (0.74) | NQO1KDM4EALDH1A1MAOBAPP | |
| SCHEMBL6059021 | 0.83 | APP (0.50) | KDM4EALDH1A1MAOBAPPDRD2 | |
| SCHEMBL23906784 | 0.81 | LTA4H (0.58) | NQO1TDP1TSHRMAPTLTA4H | |
| SCHEMBL19256954 | 0.81 | NQO1 (0.55) | NQO1KDM4EALDH1A1TDP1TSHR | |
| SCHEMBL9804312 | 0.81 | NQO1 (0.70) | NQO1KDM4EALDH1A1MAOBTDP1 | |
| SCHEMBL7928194 | 0.81 | DRD4 (0.50) | NQO1KDM4EALDH1A1DRD2DRD4 | |
| Ether SCHEMBL6687627 | 0.80 | CYP2A6 (0.50) | NQO1ALDH1A1MAPK1MAPTMMP14 | |
| SCHEMBL4064818 | 0.79 | HRH2 (0.48) | NQO1KDM4EALDH1A1MAOBDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118580171-A | Oxetane trichloroacetimidate and preparation method and application thereof | 中国科学技术大学 | 2024-09-03 | — | — | CN | disclosed |
| US-7592478-B2 | Ligand antagonists of RAR receptors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-09-22 | — | — | US | disclosed |
| US-20080213347-A1 | Novel ligand antagonists of RAR receptors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. | 2008-09-04 | — | — | US | disclosed |
| US-7348449-B2 | Ligand antagonists of RAR receptors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-03-25 | — | — | US | disclosed |
| EP-1565433-B1 | NOVEL LIGANDS THAT ARE ANTAGONISTS OF RAR RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RES & DEV (FR) | 2007-03-14 | — | — | EP | disclosed |
| US-20050234131-A1 | Novel ligand antagonists of RAR receptors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-10-20 | — | — | US | disclosed |
| EP-1565433-A2 | NOVEL LIGANDS THAT ARE ANTAGONISTS OF RAR RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | Galderma Research & Development, S.N.C. (FR) | 2005-08-24 | — | — | EP | disclosed |
| WO-2004046096-A2 | NOVEL LIGANDS THAT ARE ANTAGONISTS OF RAF RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT,S.N.C. (FR) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234131-A1 | Novel ligand antagonists of RAR receptors and pharmaceutical/cosmetic applications thereof | RARB, RARG, RARA | NQO1 487/4885KDM4E 3150/4885ALDH1A1 100/4885 |
| US-20080213347-A1 | Novel ligand antagonists of RAR receptors and pharmaceutical/cosmetic applications thereof | RARB, RARG, RARA | NQO1 473/4885KDM4E 3209/4885ALDH1A1 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.